Indonesia Biosimilars Market Size, Share & Forecast, By Product Type, Disease Area & Distribution Channel, 2026-2031

The Indonesia Biosimilars Market was valued at USD 182 million in 2025. The estimate covers domestic net sales of approved biosimilar medicines supplied through public hospitals, private hospitals, specialty clinics, pharmacies and licensed distribution channels. It excludes originator biologics, vaccines and advanced cell therapies. Oncology monoclonal antibodies represented the largest revenue pool, while epoetin and insulin-related products generated recurring treatment volumes. National insurance coverage and local registration activity supported an 11.00% historical CAGR between 2020 and 2025.

The market is forecast to expand at a CAGR of 13.60% from 2026 to 2031, reaching USD 391 million by the end of the forecast period. Growth will be driven by new product registrations, wider hospital adoption, expanded oncology and diabetes treatment and local production partnerships. Standardized treatment-unit volume should grow faster than revenue because tender competition and additional suppliers are expected to reduce average net prices. The result is a larger but increasingly cost-competitive market requiring operational scale.

Oncology monoclonal antibodies will remain the largest profit pool, particularly trastuzumab, rituximab and bevacizumab products used in breast, hematological, colorectal and lung cancers. Diabetes and nephrology will produce lower revenue per unit but more predictable repeat volumes through insulin and epoetin therapy. Profit pools will gradually shift from pure import distribution toward local licensing, fill-finish production, contract manufacturing and hospital tender management. Suppliers controlling both registration and local production will retain greater value across the supply chain.

The principal risk is the combination of regulatory evidence requirements, tender price pressure and supply-chain dependence. BPOM is modernizing its biosimilar assessment framework, requiring companies to maintain robust analytical comparability, clinical evidence, manufacturing quality and pharmacovigilance systems. At the same time, concentrated public and hospital procurement can compress net prices. Imported active substances, reference standards and specialized cold-chain components also expose suppliers to foreign-exchange, lead-time and inventory risks, particularly when demand increases faster than local production capacity.

Indonesia is estimated to rank second among the selected Southeast Asian peer markets by 2025 biosimilar value, behind Thailand and ahead of Singapore, Malaysia, Vietnam and the Philippines. Indonesia's advantage is its 285.7 million population and JKN enrollment exceeding 284 million participants. Its forecast CAGR of 13.60% is higher than Thailand and Malaysia but slightly below Vietnam and the Philippines, which are expanding from smaller bases. Indonesia therefore combines meaningful current scale with above-average regional growth.

Expansion of reimbursed specialist treatment will have the greatest impact because clinical demand already exists but remains constrained by diagnosis, referral and affordability gaps. More than 80% of Indonesian cancer patients are diagnosed at stages three or four, while measured diabetes prevalence substantially exceeds diagnosed prevalence. Government plans to expand chemotherapy, imaging, screening and referral services will increase the number of patients eligible for biologic therapy. Biosimilars can capture this demand by reducing treatment costs and enabling broader formulary inclusion.